New drug ceritinib treats ALK-positive cancer

Print
Font Size:
Default font size
Larger font size

Posted: Friday, March 28, 2014 10:14 am

A new drug called ceritinib may be effective against advanced ALK-positive non-small cell lung cancer (NSCLC), according to recent study reported in New England Journal of Medicine.

NSCLC is the leading cause of cancer death in the U.S., and around five percent of cases involve mutations in the ALK gene, which lead to uncontrolled tumor growth. The current Massachusetts General Hospital study was designed to measure the safety and tolerability of ceritinib in human patients. Ceritinib could be as much as 20 times stronger than crizotinib, which is the standard treatment agent. Researchers found similar results for both drugs.

YOUR Health and Wellness News


More about

More about

More about

Rules of Conduct

  • 1 Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
  • 2 Don't Threaten or Abuse. Threats of harming another person will not be tolerated. AND PLEASE TURN OFF CAPS LOCK.
  • 3 Be Truthful. Don't knowingly lie about anyone or anything.
  • 4 Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
  • 5 Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
  • 6 Share with Us. We'd love to hear eyewitness accounts, the history behind an article.

Welcome to the discussion.

Featured Health Care Providers Sponsored directory

CARDIOLOGY - CROUCH

F. Michael Crouch, M.D.

View Profile >

INTERVENTIONAL RADIOLOGIST

Gerald Grubbs, MD

View Profile >

PRIMARY CARE

Jack E. Baron, MD

View Profile >

SPORTS MEDICINE

John T. Moor, MD

View Profile >

GERIATRICS

Dr. Sarah Kagan, PhD, RN, FAAN

View Profile >

PROSTATE CANCER

Michael J. Dattoli, MD

View Profile >

SUBMIT PHOTOS & VIDEOS | VIEW ALL PHOTOS & VIDEOS

Send your photos & videos to Pix@MySuncoast.com and you could be featured on ABC 7 & our website.